BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Ocular Therapeutix, Inc. 

204 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-895-3235 Fax: 781-895-3236


SEARCH JOBS


Industry
Biotechnology






 Company News
Ocular Therapeutix, Inc. Begins Phase 3 Clinical Trial For Its Sustained Release Dexamethasone 3/17/2014 9:18:38 AM    More...
Ocular Therapeutix, Inc. Receives FDA Approval For The Resure® Sealant 1/9/2014 10:54:45 AM    More...
Ocular Therapeutix, Inc. Announces Phase 2 Study Results for Sustained Release Dexamethasone 10/1/2013 10:54:14 AM    More...
FDA Ophthalmic Devices Panel Favorably Votes for the Ocular Therapeutix, Inc.'s Resure® Sealant 9/20/2013 7:45:21 AM    More...
Ocular Therapeutix, Inc. Announces FDA Panel Meeting for the ReSure® Sealant 8/6/2013 10:41:44 AM    More...
Ocular Therapeutix, Inc. Wins FDA Panel Date for ReSure Sealant 8/5/2013 7:41:21 AM    More...
Baxter Ventures Invests in Ocular Therapeutix, Inc. 6/10/2013 8:18:39 AM    More...
Ocular Therapeutix, Inc. Completes Enrollment in Phase II Study for Sustained Release Dexamethasone 6/3/2013 11:27:44 AM    More...
Ocular Therapeutix, Inc. Closes on $23.8 Million Series D Extension 1/28/2013 9:55:40 AM    More...
Richard Lindstrom Joins Board of Directors at Ocular Therapeutix, Inc. 11/6/2012 9:11:42 AM    More...
123

//-->